

In Silico Analysis of Single Nucleotide Polymorphism (SNPs) in Human *RAG 1&RAG2* Genes of Severe Combined Immunodeficiency from Functional Analysis to Polymorphisms in microRNA

Mona ShamsAldeen S.Ali^{1,2,*}, Tomador Siddig M.Z.^{1,2}, Rehab A. Elhadi^{1,2}, Muhammad R.Yousof², Siddig Eltyeb Yousif Abdallah¹, Maiada Mohamed Yousif Ahmed², Nosiba Yahia Mohamed Hassen¹, Sulum Omer Masoud Mohamed¹, Marwa Mohamed Osman¹, Mohamed A. Hassan²

¹Omdurman Teaching Hospital, Sudan

²Department of Applied Bioinformatics, Africa City of Technology

*Corresponding author: mno_900@yahoo.com

Abstract Severe combined immunodeficiency (SCID) is an inherited Primary immunodeficiency PID, which is characterized by the absence or dysfunction of T lymphocytes. Defects in RAG1 and RAG2 are known to cause a T^BNK⁺ form of SCID. Recombinase activating genes RAG1 and RAG2 (OMIM 179615,179616 respectively) are expressed exclusively in lymphocytes and mediate the creation of double-strand DNA breaks at the sites of recombination and in signal sequences during T- and B- cell receptor gene rearrangement. This study was focused on the effect of nonsynonymous single nucleotide polymorphisms in the function and structure of RAG1& RAG2 genes using in silico analysis. Only nsSNPs and 3'UTR SNPs were selected for computational analysis. Predictions of deleterious nsSNPs were performed by bioinformatics software. Five damaging nsSNPs (rs112047157, rs61758790, rs4151032, rs61752933, rs75591129) were predicted in RAG1 and two damaging nsSNPs (rs112927992, rs17852002) in RAG2, all of this nsSNPs found on domain that important in binding and mutation effect in its protein function. We hope to provide more information that needed to help researchers to do further study in SCID especially in our country where consanguineous marriage is common.

Keywords: severe combined immunodeficiency (SCID), primary immunodeficiency (PID), T lymphocytes, RAG1&2, nonsynonymous Single Nucleotide Polymorphisms (nsSNP)

Cite This Article: Mona ShamsAldeen S.Ali, Tomador Siddig M.Z, Rehab A. Elhadi, Muhammad R.Yousof, Siddig Eltyeb Yousif Abdallah, Maiada Mohamed Yousif Ahmed, Nosiba Yahia Mohamed Hassen, Sulum Omer Masoud Mohamed, Marwa Mohamed Osman, and Mohamed A. Hassan, "In Silico Analysis of Single Nucleotide Polymorphism (SNPs) in Human *RAG 1&RAG2* Genes of Severe Combined Immunodeficiency from Functional Analysis to Polymorphisms in microRNA." *Biomedicine and Biotechnology*, vol. 4, no. 1 (2016): 5-11. doi: 10.12691/bb-4-1-2.

1. Introduction

Severe combined immunodeficiency (SCID) is an inherited primary immunodeficiency, which is characterized by the absence or dysfunction of T lymphocytes affecting both cellular and humoral adaptive immunity [1-5], estimated to be 1 in 75,000-100,000 of live births [8,9,10,11] and are more common in male subjects, reflecting the overrepresentation of X-linked SCID (*XL-SCID*), the most common worldwide form (~50%) of SCID in human subjects [10]. However, in cultures in which consanguineous marriage is common, the incidence of autosomal recessive (AR) SCID is higher than has been previously reported [10]. It can be classified as T-B+ and T-B- SCID with further subdivision based on the presence or absence of NK cells [5]. Defects in Recombinase activating genes (*RAG1* and *RAG2*) are

known to cause a T-B-NK+ form of autosomal recessive SCID (OMIM: 601457) [12,13].

It is now known that SCID can be caused in humans by mutations in at least 13 different genes that result in aberrant development of T cell [7]. Since the first description of *RAG1* and *RAG2* deficiency in patients with severe combined immunodeficiency by Schwarz et al. in 1996 [14], a pleiotropic spectrum of phenotypes associated with *RAG1* and *RAG2* deficiency has been described.

The location of recombination activating gene (*RAG1* & *RAG2*) is on chromosome 11 p13 [15,16]. *RAG1* and *RAG2* are expressed exclusively in lymphocytes and mediate the creation of double-strand DNA breaks at the sites of recombination and in signal sequences during T- and B-cell receptor gene rearrangement [10].

V(D)J recombination is the site-specific DNA rearrangement process that assembles the B cell receptor and TCR genes during lymphoid development. Recombination is initiated by the lymphoid-specific *RAG1*

and *RAG2* recombinase, which introduces double-strand DNA breaks at recombination signal sequences (RSSs) flanking variable (V), diversity (D), and junction (J) gene segments spread along the Immunoglobulin and TCR loci [17,18,19,20]. The recombination process is tightly regulated, occurring at specific stages of development and in specific cell types (e.g., Immunoglobulin and TCR genes are rearranged in B and T cells, respectively). This process takes place in a temporal manner, with Immunoglobulin heavy chain rearrangements preceding Immunoglobulin light chain rearrangements and D-to-J rearrangements preceding V-to-DJ rearrangements [17,18,19,20]. Mutations in either *Rag1* or *Rag2* genes hamper initiation of V(D)J recombination, hence causing an early block of B and T cell maturation similar to the situation of *Rag1* and *Rag2* knockout (KO) mice [21].

In this computational study, we focused on the effect of nsSNPs in the function and structure of *RAG 1 and RAG 2* Protein using *in silico* analysis. Hence it is the first study type of *RAG1* and *RAG2* analysis, we hope to provide more information that needed to help researchers to do further study in SCID especially in our country where consanguineous marriage is common.

2. Materials and Methods

The SNPs sequence of *RAG1 and RAG 2* genes were collected in August 2015 from NCBI database (<http://www.ncbi.nlm.nih.gov/projects/SNP>). They contained a total of 5413 SNPs in *RAG1* and 2804 SNPs in *RAG2* at the time of the study, out of which 1048 in *RAG1* and 508 in *RAG2* were coding SNPs, 147 in *RAG1* and 28 in *RAG2* occurred in the miRNA 3' UTR, 8 in *RAG1* and 10 in *RAG2* occurred in 5' UTR region and 234 in *RAG1* and 178 in *RAG2* occurred in intronic regions. We selected missense & nonsense nsSNPs and 3' UTR SNPs for our investigation, Figure 1. The nsSNPs (rs SNPs) of *RAG 1&2* were submitted as batch to SIFT server, then the resultant damaging nsSNPs were submitted to Polyphen as query sequences in FASTA Format. Prediction of change in stability due to mutation was performed by I-Mutant 2.0. The protein sequences used were obtained from the ExPASy Database (www.expasy.org). Project hope

software was used to highlight the changes occurred as a result of the deleterious SNPs at the molecular level of the protein 3D structure. The SNPs at the 3' UTR region were analyzed by Polymirt software. Prediction of the function of genes and their interactions were obtained from GENEMANIA database.

GeneMANIA (<http://www.genemania.org/>): is an online database that helps you predict the function of your favorite genes and gene sets. GeneMANIA finds other genes that are related to a set of input genes, using a very large set of functional association data. Association data include protein and genetic interactions, pathways, co-expression, co-localization and protein domain similarity. You can use GeneMANIA to find new members of a pathway or complex, find additional genes you may have missed in your screen or find new genes with a specific function, such as protein kinases. Your question is defined by the set of genes you input [22].

SIFT-software In order to detect deleterious nsSNPs SIFT program was used, which is a novel bioinformatics tool to predict whether an amino acid substitution affects protein function, this program generates alignments with a large number of homologous sequences and assigns score for each residue ranging from zero to one. Scores closer to zero indicates evolutionary conservation of the genes and intolerance to substitution, while scores closer to one indicate tolerance to substitution only [23]. (<http://sift.jcvi.org/>).

PolyPhen-2 Also is an online bioinformatics software produced by Harvard university it searches for 3D protein structures, then calculates position-specific independent count scores (PSIC) for each of two variant and the computes the PSIC scores difference between two variants. PolyPhen results were assigned probably damaging (2.00 or more) possibly damaging (1.40-1.90), potentially damaging (1.0-1.5), benign (0.00-0.90), [24]. (<http://genetics.bwh.harvard.edu/pph2/index.shtml>). We used this software to confirm SIFT result and we took only double positive results for further workup.

I-Mutant v2.0c Predictor the stability changes upon mutation from the protein sequence or structure. It shows the amino acid in Wild-Type Protein (WT), New Amino acid after Mutation (NAW), reliability Index (RI), Temperature in Celsius degrees (T) and the PH [25].




Figure 1. distribution of nonsynonymous, 5' UTR, 3' UTR and intronic SNPs for *RAG1&2*

I-Mutant available at: (<http://www.I-Mutant2.0.cgi>).

Chimera is software produced by University of California, San Francisco is used in this step to generate the mutated models of ATP7B protein 3D model. The outcome is then a graphic model depicting mutation [26]. (<http://www.cgl.ucsf.edu/chimera/>).

Project Hope software (<http://www.cmbi.ru.nl/hope/input>) is an online web service where the user can submit a sequence and mutation. This software collects structural information from a series of sources, including calculations on the 3D protein structure, sequence annotations in UniProt and predictions from DAS-servers. It combines this information to give analyze the effect of a certain mutation on the protein structure and will show the effect of that mutation in such a way that even those without a bioinformatics background can understand it [27].

PolymiRTS is the database server designed specifically for the analysis of the 3UTR region, we used this server to determine SNPs that may alter miRNA target site [28]. All SNPs located within the 3UTR region were selected separately and submitted to the program. (Available at: <http://compbio.uthsc.edu/miRSNP/>).

3. Results

Recombination activating proteins 1&2 have many vital functions. Also these genes co-expressed with, share similar protein domain, or participate to achieve similar function are illustrated by using GENEMANIA and shown in [Figure 2](#) below.




Figure 2. functions and interaction of *RAG1* and *RAG2* with functional similar genes was predicted using Gene MANIA software

Table 1. Prediction of nsSNPs in *RAG 1* & *RAG 2* by SIFT, Polyphen-2 and I-Mutant software

Gene Type	SNP ID	Chromosome Location	Nucleotide Change	Sift Prediction	Sift Score	Sift Medium	Acc	Amino Acid Change	Polyphen-2 Result	I Mutant Result
<i>RAG1</i>	rs112047157	11:36574763	A/G	Damage	1.000.00	4.27	P15918	M487V	Possibly Damaging	Decrease stability
	rs61758790	11:36574864	G/T	Damage	1.000.00	4.27		F520L	Probably Damaging	Increase stability
	rs4151032	11:36574877	C/T	Damage	1.000.00	4.27		P525S	Probably Damaging	Decrease stability
	rs61752933	11:36575732	A/G	Damage	1.000.01	4.27		I810V	Possibly Damaging	Increase stability
	rs75591129	11:36576096	A/C	Damage	1.000.00	4.27		Y931S	Probably Damaging	Decrease stability
<i>RAG2</i>	rs112927992	11:36614847	C/T	Damage	1.000.00	4.32	p55895	S291F	Possibly Damaging	Decrease stability
	rs17852002	11:36615258	T/C	Damage	1.000.00	4.32		V154A	Probably Damaging	Decrease stability

3.1. Prediction of Protein Structural Stability

Seven nsSNPs of *RAG1*&*2* genes have been selected on the basis of prediction scores of Sift and polyphen; these SNPs were given to I-Mutant web server to predict the DDG stability and reliability index (RI) upon mutation, in *RAG1*, three SNPs (rs112047157, rs4151032 and rs75591129) shown decrease in protein stability while other two SNPs (rs61758790 and rs61752933) shown increase in protein stability. Both SNPs in *RAG2* predicted to decrease protein stability, Table 1.

3.2. Modeling of Mutant Structure

Protein sequences of the nsSNP were presented to Project Hope revealed the 3D structure for the truncated proteins with its new candidates; in addition, it described the reaction and physiochemical properties of these candidates. Here we present the results upon each candidate and discuss the conformational variations and interactions with the neighboring amino acids; All native and mutant structure of *RAG1* & *2* proteins showed in the [Figure 3](#) and the wild type is displayed by green color while mutant type is displayed by red one.

3.3. SNPs at the 3'UTR Region

SNPs in 3'UTR of *RAG1*, *2* genes were submitted as batch to PolymiRTS server. The output showed result as following; in *RAG1*, 19 SNPs were predicted while only three SNPs were predicted in *RAG2* gene. The functional classes of both genes are described in Table 2 below.








No.	SNP ID	GENE TYPE	3D STRUCTURE	DESCRIPTION
1	rs112047157	<i>RAG1</i>		changed from Methionine to Valine at position 487
2	rs61758790			changed from Phenylalanine to Leucine at position 520
3	rs4151032			changed from Proline to Serine at position 525
4	rs61752933			changed from Isoleucine to Valine at position 810
5	rs75591129			changed from Tyrosine to Serine at position 931
6	rs112927992	<i>RAG2</i>		changed from Serine to Phenylalanine at position 291
7	rs17852002			changed from Valine to Alanine at position 154

Figure 3. 3D model by Chimera and Project HOPE for RAG1&2 proteins

Table 2.A. 3'UTR SNPs of *RAG1* as detected by PolymiRTS

Location	dbSNP ID	miR ID	Cancer type	miR site	Function class	context+ score change
36598009	rs189589191	hsa-miR-548	Cervical cancer	tgagtGGGTTTt	Disrupted	-0.102
		hsa-miR-4637	acute lymphoblastic leukemia	tgAGTTAGTttt	Created	-0.176
36598259	rs144069419	hsa-miR-3191	Melanoma	aCCAGAGAtgagc	Disrupted	-0.136
		hsa-miR-330	Cervical cancer	aCCAGAGAtgagc	Disrupted	-0.081
		hsa-miR-3126	Melanoma & breast cancer	aCCAGATAtgagc	Created	-0.089
36598426	rs115582302	hsa-miR-3646	solid tumors	tatTTCATTTtg	Disrupted	-0.067
36598426	rs115582302	hsa-miR-548ad	malignant human B cells	tattTCGTTTtg	Created	-0.187
36598725	rs4151039	hsa-miR-3137	Melanoma	taGCTACAGttag	Disrupted	-0.224

Location	dbSNP ID	miR ID	Cancer type	miR site	Function class	context+score change
36599069	rs4151040	hsa-miR-624	colorectal cancer	ggataACCTTGTA	Disrupted	-0.129
36599086	rs112766186	hsa-miR-4524	malignant human B cells + breast cancer	tcctCTGCTAAg	Created	-0.034
36599087	rs145963034	hsa-miR-374	cervical cancer	ccatccGCTAAGT	Disrupted	-0.037
36599090	rs4151041	hsa-miR-374	cervical cancer	tccGCTAAGTtta	Disrupted	-0.037
36599164	rs149724031	hsa-miR-570	colorectal cancer	tggaaTGTTTTCA	Disrupted	0.1
36599261	rs113060327	hsa-miR-5195	acute lymphoblastic leukemia	tcattTAGGGGTA	Disrupted	-0.282
		hsa-miR-4640	Breast cancer	tcattGGGGGTA	Created	-0.158
36599548	rs185464049	hsa-miR-5694	metastatic prostate cancer	gaaactATGATCT	Disrupted	0.076
		hsa-mir-27	cervical cancer	gaaACTGTGAtct	Created	0.024
36599964	rs4151044	hsa-miR-3153	Melanoma	gccacaCTTTCCC	Disrupted	-0.003
		hsa-miR-4668	Breast cancer	gccacaTTTTCCC	Created	0.056
36600151	rs148483119	hsa-miR-155	B cell lymphomas + cervical cancer + CLL	taacacTGTAGGA	Disrupted	-0.079
36600232	rs4151045	hsa-miR-4698	Breast cancer	atcaCATTTTGAT	Disrupted	0.095
		hsa-miR-3973	acute myeloid leukemia	atcacACTTTGAt	Created	0.035
		hsa-miR-595	colorectal cancer	atCACACTTgat	Created	-0.052
36600527	rs192931118	hsa-miR-3622	Cervical + breast cancer	TCAGGTGcattgc	Disrupted	-0.043
36601006	rs180966342	hsa-miR-580	colorectal cancer	AATCATTTtggT	Disrupted	-0.099
36601142	rs183729240	hsa-miR-1273	cervical cancer	gatGCAGTGGAtt	Created	-0.466
		hsa-miR-181	cervical cancer + CLL	gatgCAGTGGAtt	Created	-0.165
36601202	rs190801060	hsa-miR-205	cervical cancer + nasopharyngeal carcinoma	aaaTGAAATatga	Disrupted	-0.057
		hsa-miR-5696	metastatic prostate cancer	AAATGAAaatga	Disrupted	-0.035
		hsa-miR-579	colorectal cancer	AAATGAAaatga	Disrupted	-0.059

Table 2B. 3'UTR SNPs of *RAG2* as detected by PolymiRTS

Location	dbSNP ID	miR ID	Cancer type	miR site	Func class	context+score change
36613631	rs186462541	hsa-miR-1273	Cervical cancer	tTCAAGCAAccct	disrupted	-0.322
		hsa-miR-23	Cervical cancer	ttcaaGGAACCCt	Created	-0.319
	rs3740956	hsa-miR-193	Cervical cancer	taGCCAGTAaaga	Created	-0.226
36613758		hsa-miR-4794	Breast cancer	TAGCCAGTaaaga	Created	-0.276
		hsa-miR-664	Chronic lymphocytic leukemia	TAGCCAGTaaaga	Created	-0.294
36613947	rs142073874	has-miR-4698	Breast cancer	cctataCATTTTG	disrupted	-0.194

4. Discussion & Conclusion

In *RAG1* we found five nsSNPs predicted by SIFT & polyphen and five nsSNP (rs415107, rs34841221, rs4151029, rs2227973, rs4151034) are damaging by SIFT only. In *RAG2* we found two nsSNPs predicted damaging by both SIFT & polyphen, however one nsSNP (rs117899975) is damaging by SIFT only.

A/G mutation (rs112047157): methionine 487 valine, This residue is part of an interpro domain named Recombination-Activation Protein 1 (IPR024627). This domain is annotated with the Gene-Ontology (GO) that indicate the domain has a function in DNA Binding (GO:0043565), Nucleic Acid Binding (GO:0003676). The mutant residue is smaller than wild residue; this might lead to loss of interactions, so it might be too small to make multimer contacts. The wild-type residue is located in an α -helix. The mutation converts the wild-type residue in a residue that does not prefer α -helices as secondary structure. The mutated residue is located in a domain that is important for binding of other molecules. Mutation of the residue might disturb the function. (Figure 3-1)

G/T mutation (rs61758790): phenylalanine 520 leucine, the wild-type residue is located in its preferred secondary structure, a β -strand. This residue is part of an interpro domain named Recombination-Activation Protein 1 (IPR024627). This domain is annotated with the Gene-Ontology (GO) that indicate the domain has a function in DNA Binding (GO:0043565), Nucleic Acid

Binding (GO:0003676). The mutant residue is smaller than wild residue, this might lead to loss of interactions. The mutant residue prefers to be in another secondary structure; therefore the local conformation will be slightly destabilized. The mutated residue is located in a domain that is important for binding of other molecules. Mutation of the residue might disturb this function. (Figure 3-2).

C/T mutation (rs4151032): proline 525 serine, prolines are known to have a very rigid structure, sometimes forcing the backbone in a specific conformation, changes a proline with such a function into another residue disturbing the local structure. This variant is annotated with severity: POLYMORPHISM (VAR_029263). This residue is part of an interpro domain named Recombination-Activation Protein 1 (IPR024627). This domain is annotated with the Gene-Ontology (GO) that indicate the domain has a function in DNA Binding (GO:0043565), Nucleic Acid Binding (GO:0003676). The mutant residue is smaller than wild residue; this might lead to loss of interactions. The wild-type residue is more hydrophobic than the mutant residue. Hydrophobic interactions, either in the core of the protein or on the surface, will be lost. The mutated residue is located in a domain that is important for binding of other molecules. Mutation of the residue might disturb this function, (Figure 3-3)

A/G mutation (rs61752933): isoleucine 810 valine, this residue is part of an interpro domain named Recombination-Activation Protein 1 (IPR024627). This

domain is annotated with the Gene-Ontology (GO) that indicate the domain has a function in DNA Binding (GO:0043565), Nucleic Acid Binding (GO:0003676). The mutant residue is smaller than wild residue; this might lead to loss of interactions. The mutated residue is located in a domain that is important for binding of other molecules. Mutation of the residue might disturb this function, (Figure 3-4)

A/C mutation (rs75591129): tyrosine 931 serine, the wild-type residue is preferred secondary structure, a β -strand. The mutant residue prefers to be in another secondary structure; therefore the local conformation will be slightly destabilized. This residue is part of an interpro domain named Recombination-Activation Protein1 (IPR024627). This domain is annotated with the Gene-Ontology (GO) that indicate the domain has a function in DNA Binding (GO:0043565), Nucleic Acid Binding (GO:0003676). The mutated residue is located in a domain that is important for binding of other molecules. Mutation of the residue might disturb this function, (Figure 3-5).

C/T mutation (rs112927992): serine 291 phenylalanine, this residue is part of an interpro domain named V-D-J Recombination Activating Protein 2 (IPR004321). This domain is annotated with Gene-Ontology (GO) these GO annotations indicate the domain has a function in DNA binding (GO:0003677), Nucleic Acid Binding (GO:0003676). This residue is part of an interpro domain named Galactose Oxidase/kelch, Beta-Propeller (IPR011043). The mutant residue is bigger than the wild-type residue, this might lead to bumps. The mutant residue is more hydrophobic than the wild-type residue; this can result in loss of hydrogen bonds and/or disturb correct folding. The mutated residue is located in a domain that is important for binding of other molecules. Mutation of the residue might disturb this function, (Figure 3-6).

T/C mutation (rs17852002): valine 154 alanine, the wild-type residue is located in its preferred secondary structure, a β -strand. The mutant residue is smaller than the wild residue; this might lead to loss of interactions. The mutant residue prefers to be in another secondary structure; therefore the local conformation will be slightly destabilized. The residue is part of an interpro domain named V-D-J Recombination Activating Protein 2 (IPR004321). This domain is annotated with Gene-Ontology (GO) these indicate the domain has a function in DNA binding (GO:0003677), Nucleic Acid Binding (GO:0003676), also is part of an interpro domain named Galactose Oxidase/kelch, Beta-Propeller (IPR011043), is part of an interpro domain named Kelch-Type Beta Propeller (IPR015915), the domain is also important in Protein Binding (GO:0005515), (Figure 3-7).

Both nsSNPs of RAG2 were found in the same domain that important in function of protein leading to disturb of function. Mutations in RAG1 or RAG2 result in the blocking of T- and B-cell development secondary to the inability to initiate recombination of the DNAs variable, diversity, and joining regions, and thereby do not form functional T-cell or B-cell receptors [29].

According to Table 2, we found some SNPs in 3UTR of both RAG 1&2 related to cancer development although those patients with SCID don't survive [8,9,10] till they develop cancer, but some patients with delayed onset of RAG1 deficiency develop cancer [30].

Our results from this study suggest that the application of computational tools including SIFT, PolyPhen-2, I Mutant 2v, polymRTS, Chimera and Project Hope might provide an alternative approach to select target SNPs in association studies.

Acknowledgements

The authors thank the Africa City of Technology (Sudan) for providing the facilities to carry out this work.

Competing Interests

The authors declare that they have no competing interests.

References

- [1] Notarangelo LD. Primary immunodeficiencies. *J Allergy ClinImmunol.* 2010; 125: S182-S194.
- [2] Fausto Cossu. Genetics of SCID. *Ital J Pediatr.* 2010; 36: 76.
- [3] Jennifer M. Puck, MD. Laboratory Technology for Population-based Screening for SCID in Neonates: The Winner Is T-cell Receptor Excision Circles (TRECs). *J Allergy ClinImmunol.* 2012 Mar; 129(3): 607-616.
- [4] Jennifer M. Puck. The case for newborn screening for severe combined immunodeficiency and related disorders. *Ann N Y Acad Sci.* 2011 Dec; 1246: 108-117.
- [5] Mirjam van der Burg & Andy R. Gennery. The expanding clinical and immunological spectrum of severe combined immunodeficiency. *Eur J Pediatr* (2011) 170: 561-571.
- [6] Vries E, Driessen G. Educational paper: primary immunodeficiencies in children: a diagnostic challenge. *Eur J Pediatr.* 2011; 170: 169-177.
- [7] Rebecca H. Buckley, M.D. Transplantation of Hematopoietic Stem Cells in Human Severe Combined Immunodeficiency: Longterm Outcomes. *Immunol Res.* 2011 Apr; 49(0): 25-43.
- [8] Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, Roberts JL, Puck JM. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. *J Pediatr.* 1997; 130: 378-87.
- [9] Stephan JL, Vlekova V, Le Deist F, De Saint Basile G, Donadieu J, Durandy A, Blanche S, Griscelli C, Fischer A. A retrospective single-center study of clinical presentation and outcome in 117 patients with severe combined immunodeficiency. *Immunodeficiency.* 1993; 4: 87-8.
- [10] Diana Tasher and Ilan Dalal. The genetic basis of severe combined immunodeficiency and its variants. *Appl Clin Genet.* 2012; 5: 67-80.
- [11] Fischer A. Severe combined immunodeficiencies (SCID) *ClinExpImmunol.* 2000; 122: 143-149.
- [12] Niek P van Til, Helen de Boer, Nomusa Mashamba, Agnieszka Wabik, Marshall Huston, Trudi P Visser, Elena Fontana, Pietro Luigi Poliani, Barbara Cassani, Fang Zhang, Adrian J Thrasher, Anna Villa, and Gerard Wagemaker. Correction of Murine *Rag2* Severe Combined Immunodeficiency by Lentiviral Gene Therapy Using a Codon-optimized *RAG2* Therapeutic Transgene. *MolTher.* 2012 Oct; 20(10): 1968-1980.
- [13] Corneo, B., Moshous, D., Gungor, T., Wulffraat, N., Philippet, P., Le Deist, F., Fischer, A., de Villartay, J.-P. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. *Blood* 97: 2772-2776, 2001.
- [14] Christoph B.Geier, Alexander Piller, Angela Linder, Kai M. T.Sauerwein, Martha M. Eibl and Hermann M.Wolf.Leaky RAG Deficiency in Adult Patients with Impaired Antibody Production against Bacterial Polysaccharide Antigens. *PLoS One.* 2015; 10(7): e0133220.
- [15] Sherrington, P. D., Forster, A., Seawright, A., van Heyningen, V., Rabbitts, T. H. Human RAG2, like RAG1, is on chromosome 11

- band p13 and therefore not linked to ataxia telangiectasia complementation groups. *Genes Chromosomes Cancer* 5: 404-406, 1992.
- [16] Oettinger, M. A., Stanger, B., Schatz, D. G., Glaser, T., Call, K., Housman, D., Baltimore, D. The recombination activating genes, RAG1 and RAG2, are on chromosome 11p in humans and chromosome 2p in mice. *Immunogenetics* 35: 97-101, 1992.
- [17] Chrystelle Couédel, Christopher Roman, Alison Jones, Paolo Vezzoni, Anna Villa, and Patricia Cortes. Analysis of mutations from SCID and Omenn syndrome patients reveals the central role of the Rag2 PHD domain in regulating V(D)J recombination. *J Clin Invest.* 2010 Apr 1; 120(4): 1337-1344.
- [18] Min-Sung Kim, Mikalai Lapkouski, Wei Yang, and Martin Gellert. Crystal Structure of the V(D)J Recombinase RAG1-RAG2. *Nature.* 2015 Feb 26; 518(7540): 507-511.
- [19] Nathalie Nicolas, Despina Moshous, Marina Cavazzana-Calvo, Dora Papadopoulo, Régina de Chasseval, Françoise Le Deist, Alain Fischer, and Jean-Pierre de Villartay. A Human Severe Combined Immunodeficiency (SCID) Condition with Increased Sensitivity to Ionizing Radiations and Impaired V(D)J Rearrangements Defines a New DNA Recombination/Repair Deficiency. *J Exp Med.* 1998 Aug 17; 188(4): 627-634.
- [20] Yu-Hang Zhang, Keerthi Shetty, Marius D. Surleac, Andrei J. Petrescu and David G. Schatz. Mapping and Quantitation of the Interaction between the Recombination Activating Gene Proteins RAG1 and RAG2. May 8, 2015 *The Journal of Biological Chemistry*, 290, 11802-11817.
- [21] Paola Rivera-Munoz, Laurent Malivert, Sonia Derdouch, Chantal Azerrad, Vincent Abramowski, Patrick Revy and Jean-Pierre de Villartay. DNA repair and the immune system: From V(D)J recombination to aging lymphocytes. *Eur. J. Immunol.* 2007. 37: S71-82.
- [22] David Warde-Farley, QM, Sylva L., Donaldson Ovi, Comes Khalid, Zuberi Rashad, Badrawi Pauline, Chao Max, Franz Chris, Grouios Farzana, Kazi Christian, Tannus Lopes, Anson Maitland, Sara Mostafavi, Jason Montojo, Quentin Shao, George Wright, Gary D. Bader. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res.* 2010; 38: W214-W2.
- [23] Ng PC, Henikoff S (2001). Predicting deleterious amino acid substitutions. *Genome Res* 11:863-874.
- [24] V. Ramensky, P. Bork, S. Sunyaev, Human non-synonymous SNPs: server and survey, *Nucleic Acids Res.* 30 (2002) 3894-3900.
- [25] Capriotti E, Calabrese R, Casadio R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. *Nucleic Acids Res.* 2005; (33): 306-10.
- [26] Pettersen EF, Goddard TD, Huang CC, et al. (2004). Comput UCSF Chimera—a visualization system for exploratory research and analysis. *Chem.* 25(13): 1605-12.
- [27] Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics.* 2010; 11(1):548.
- [28] Bhattacharya A. Ziebath JD and Cui Y. (2014). PolmiRTS Database 3.0: Linking polymorphisms in microRNAs and their target sites with human diseases and biological pathway. *Nucleic Acids Res.* 42(D1): D86-D91.
- [29] Brian T Kelly, Jonathan S Tam, James W Verbsky, and John M Routes. Screening for severe combined immunodeficiency in neonates. *ClinEpidemiol.* 2013; 5: 363-369.
- [30] Hassan Abolhassani, Ning Wang, Asghar Aghamohammadi, MD, PhD, Nima Rezaei, Yu Nee Lee, Francesco Frugoni, Luigi D. Notrangelo, Qiang Pan-Hammarström and Lennart Hammarström. A Hypomorphic RAG1 Mutation Resulting in a Phenotype Resembling Common Variable Immunodeficiency. *J Allergy Clin Immunol.* 2014 Dec; 134(6): 1375-1380.